drugset / Trial / NCT02853903
Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors
Phase 2
Completed
20 enrolled
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is the efficacy of autogenic and allogenic natural killer (NK) immunotherapy on recurrent solid tumors.
Timeline
- Start
- 2016-07-01
- Primary completion
- 2017-07-01
- Completion
- 2019-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NK immunotherapy | Cell therapy | 8e+09 cells | Intravenous |
| Subject | NK immunotherapy | Cell therapy | 1e+10 cells | Intravenous |